Moxonidine treatment of hypertensive patients with advanced renal failure

Journal of Hypertension

Volumn 21, Issue 9, 2003, Pages 1709-1717

  Vonend, Oliver ^a   Marsalek, Parvaneh ^b   Russ, Hagen ^b   Wulkow, Ralf ^c   Oberhauser, Vitus ^a   Rump, Lars C ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c IQVIA   (United States)

Author keywords

Antihypertensive drugs; Chronic renal failure; Hypertension; Moxonidine; Nitrendipine; Progression; Safety; Sympathetic nervous system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDRALAZINE; MOXONIDINE; NITRENDIPINE;

ADULT; AGED; AGRANULOCYTOSIS; ALLERGIC REACTION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRADYCARDIA; BREATHING DISORDER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; EXTRASYSTOLE; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GYNECOMASTIA; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; LEG EDEMA; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SLEEP DISORDER; SYMPATHETIC BLOCKING; TACHYCARDIA; TREMOR; URTICARIA; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0042733634     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200309000-00021     Document Type: Article

References (35)

1. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997; 30:428-435.
2. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI. Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996; 27:245-250.
3. Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40:583-596.
4. Del Vecchio L, Locatelli F. The renoprotective effect of combined antihypertensive drugs. J Nephrol 2001; 14:7-14.
5. Epstein M. Calcium antagonists and the progression of chronic renal failure. Curr Opin Nephrol Hypertens 1998; 7:171-176.
6. Lederle RM. The effect of antihypertensive therapy on the course of renal failure. J Cardiovasc Pharmacol 1992; 20(suppl 6):S69-S72.
7. Rodicio JL, Morales JM, Alcazar JM, Ruilope LM. Calcium antagonists and renal protection. J Hypertens 1993; 11(suppl 1):S49-S53.
8. Ruilope LM, Araque A, Lahera V, Suarez C. Antihypertensive effect of nitrendipine in the hypertensive patient with renal impairment. Ren Failure 1993; 15:359-363.
9. Epstein M, Tobe S. What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure? Curr Hypertens Rep 2001; 3:422-428.
10. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant 1998; 13:3091-3095.
11. Campese VM. Is hypertension in chronic renal failure neurogenic in nature? Nephrol Dial Transplant 1994; 9:741-742.
12. Rump LC. The role of sympathetic nervous activity in chronic renal failure. Clin Basic Cardiol 2001; 4:179-182.
13. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002; 20:3-9.
14. Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264:172-182.
15. Prichard BN. Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994; 8(suppl 1):49-58.
16. Kirch W, Hutt HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990; 30:1088-1095.
17. Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15:245-253.
18. Chrisp P, Faulds D. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992; 44:993-1012.
19. Prichard BN, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997; 15(suppl 1):S47-S55.
20. Jaeger B, Verboom C, Brunner H. The clinical efficacy of moxonidine in hypertension. Rev Contemp Pharmacother 1998; 9:463-471.
21. Schachter M, Luszick J, Jager B, Verboom C, Sohlke E. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf 1998; 19:191-203.
22. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11:1469-1478.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
24. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357:1601-1608.
25. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252-1256.
26. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87.
27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
28. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-762.
29. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
30. Sides GD, Leschinger MI, Walenta R, McNay JLJ. The tolerability and adverse event profile of moxonidine. Rev Contemp Pharmacother 1998; 9:491-498.
31. Schachter M. Moxonidine: a review of safety and tolerability after seven years of clinical experience. J Hypertens 1999; 17(suppl 3):S37-S39.
32. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998; 13:1430-1437.
33. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept 1994; 50:259-265.
34. Szabo B, Bock C, Nordheim U, Niederhoffer N. Mechanism of the sympathoinhibition produced by the clonidine-like drugs rilmenidine and moxonidine. Ann NY Acad Sci 1999; 881:253-264.
35. Bohmann C, Schollmeyer P, Rump LC. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn Schmiedebergs Arch Pharmacol 1994; 349:118-124.